Second Patent Issued for Healionics’ Textured STAR Biointerface

Healionics Corporation has received a further patent for its textured STAR Biointerface technology. The United States Patent and Trademark Office issued Patent No. 8,647,393, "Implantable Medical Devices Having Microporous Surface Layers and Method for Reducing Foreign Body Response to the Same.” This new patent extends the scope of 8,372,423 issued to Healionics in February 2013.

The STAR Biointerface is a textured porous tissue ingrowth layer that enhances the biocompatibility and infection resistance of implanted medical devices. The ingrowth layer can be formed by adhering granules of a porous biomaterial to a device surface.
Invented by Healionics, the STAR Biointerface complements Healionics’ exclusively licensed STAR Biomaterial technology that served as the intellectual property foundation for the company.

“The new patent includes claims covering methods for reducing risk of implantable device-related infection and for reducing foreign body response,” said Andrew Marshall, CTO and co-inventor.

“This represents a further important step for our qSTAR Medical vascular access device program,” added President and co-inventor Max Maginness.

About Healionics Corporation
Healionics develops and manufactures STAR Biomaterials for implanted medical devices. The precisely controlled pore structure of the innovative STAR technology induces a favorable integrated healing response, overcoming fibrotic reactions and infection issues to enhance medical device performance and longevity.

About qSTAR Medical SAS
qSTAR Medical is a startup medical device company whose mission is to improve the lives of people suffering from End Stage Renal Disease (ESRD). qSTAR’s initial focus is to develop “next generation” vascular access implants featuring the innovative STAR Biomaterial.